Avenue Therapeutics, Inc. (ATXI)
OTCMKTS · Delayed Price · Currency is USD
0.3098
+0.0098 (3.27%)
May 18, 2026, 1:40 PM EST
Avenue Therapeutics Company Description
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting.
Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain.
The company was incorporated in 2015 and is based in New York, New York.
Avenue Therapeutics, Inc.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Alexandra MacLean |
Contact Details
Address: 1111 Kane Concourse Bay Harbor Islands, Florida Florida United States | |
| Phone | 781 652 4500 |
Stock Details
| Ticker Symbol | ATXI |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US05360L3042 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alexandra MacLean M.D. | Chief Executive Officer and Director |
| David Jin | Interim Chief Financial Officer, Chief Operating Officer and Corporate Secretary |
| Dr. Lindsay Allan Rosenwald M.D. | Executive Director |